Rezolute, Inc.
NASDAQ:RZLTBiotechnology
+$0.30 today
- Market cap
- $411.10M
- Beta
- 0.65
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.78
Volume 2.93M
Average 2.03M
RZLT Long-term Debt
Borrowings due after more than one year.
Rezolute, Inc.NASDAQ: RZLT
Long-term Debt · Q3 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q3 FY2026 long-term debt was $0, compared with $0 a year earlier.
Context
- Long-term debt amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Long-term debt increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 0 | — |
| FY2024 | 2024-06-30 | 0 | — |
| FY2023 | 2023-06-30 | 0 | — |
| FY2022 | 2022-06-30 | 0 | -100.0% |
| FY2021 | 2021-06-30 | 13.97M | — |
Long-term Debt vs competitors
How RZLT compares with its peers on the latest reported figures
- RZLT's Mar 2026 long-term debt of $0 is the 4th highest of the 5 companies compared; the peer median is $47.07M.
- Long-term debt amounts to 0.0% of total assets for RZLT, versus a peer median of 9.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.13B | — | — | 87.0% | |
| Mar 2026 | $93.39M | +11.4% | -11.0% | 19.1% | |
| Mar 2026 | $741K | -98.8% | +69.1% | 0.3% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RZLT) | $47.07M | -43.7% | +29.1% | 9.7% | |
Competitors are the stored peer set for RZLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 41.05M | 150.41M | 16.04M | 70.4M | 94.11M |
| Short-term Investments | 0 | 0 | 85.86M | 56.48M | 73.75M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 1.78M | 3.29M |
| Total Current Assets | 41.99M | 152.1M | 104.91M | 128.65M | 171.15M |
| Property, Plant & Equipment (Net) | 425K | 168K | 2.19M | 1.98M | 1.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 16.47M | 263K | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 191K | 148K | 148K | 1.84M | 2.93M |
| Total Non-current Assets | 616K | 316K | 18.81M | 4.08M | 4.35M |
| Total Assets | 42.61M | 152.42M | 123.72M | 132.74M | 175.49M |
| Account Payables | 1.04M | 1.13M | 3.27M | 4.9M | 5.81M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 77K | 0 | 883K | 1.81M | 2.27M |
| Total Current Liabilities | 1.97M | 2.46M | 5.2M | 9.61M | 11.91M |
| Long-term Debt | 13.97M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 387K | 407K | 412K | 468K | 468K |
| Total Non-current Liabilities | 14.54M | 487K | 2.35M | 2.13M | 1.45M |
| Total Liabilities | 16.51M | 2.95M | 7.55M | 11.73M | 13.36M |
| Common Stock | 8K | 34K | 37K | 53K | 87K |
| Retained Earnings | (168.14M) | (209.2M) | (260.99M) | (329.44M) | (403.86M) |
| Accumulated OCI | 0 | 0 | (351K) | (79K) | (7K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 26.1M | 149.47M | 116.17M | 121M | 162.13M |
| Total Debt | 14.42M | 188K | 2.48M | 2.23M | 1.62M |
| Net Debt | (26.63M) | (150.22M) | (13.56M) | (68.17M) | (92.49M) |
Rezolute, Inc.
NASDAQ:RZLT
Intrinsic Alpha fair value
Locked
Current Price
$4.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.